Spots Global Cancer Trial Database for KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Official Title: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors
Study ID: NCT06026410
Study Description
Brief Summary: This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Southern California, Los Angeles, California, United States
UCLA Department of Medicine, Los Angeles, California, United States
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
AdventHealth Celebration, Celebration, Florida, United States
Florida Cancer Specialists, Sarasota, Florida, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
OU Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
SCRI - Oncology Partners, Nashville, Tennessee, United States
University of Wisconsin (Carbone Cancer Center), Madison, Wisconsin, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
